Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
Not Applicable
Completed
- Conditions
- Glaucoma, Primary Open Angle
- Interventions
- Registration Number
- NCT04737928
- Lead Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
- Brief Summary
The objective of this study was to investigate the improving effect of corneal disorder in primary open-angle glaucoma and ocular hypertension patients, when switched from the 0.005% latanoprost ophthalmic solution (one drop at a time, once daily) to the 0.0015% tafluprost ophthalmic solution (one drop at a time, once daily). Efficacy also was investigated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
- Age of 20 years or older and those who was provided informed consent.
- POAG or OH patients whose IOP did not exceed 22 mmHg at Visit 0.
- Patients had treated with prostaglandin ophthalmic solution (0.005% Latanoprost) for at least 3 months before enrollment.
- Patients who had corneal disorders due to the PG usage. (At least one eye had a score above 1 on the NEI scale)
- If only one eye was eligible, it was evaluated. When both eyes were eligible, then the eye with a higher NEI score was selected for evaluation.
- Outpatients who visited the clinic on the designated day as instructed by the physician.
Exclusion Criteria
- Those with severe visual field disorder (Mean deviation of 15 dB or worse).
- Those who received corneal refractive surgery.
- Those with a history of ocular surgeries (such as corneal refractive surgery, intraocular surgery including ocular laser treatment which affected the patient's ocular surface condition) within 3 months prior to enrollment.
- Any corneal abnormality or other condition preventing IOP measurement.
- Those who used artificial tears to relieve dry eye symptoms.
- Those with severe dry eye, ocular allergy, ocular infection or ocular inflammation which considered affect interpretation of the results of the study. Those who used systemic or ophthalmic steroids (excluding topical skin steroidal ointment) and anti-glaucoma agents other than prostaglandin ophthalmic solution.
- Female patients who were pregnant, nursing or lactating.
- Those with a history of drug allergy (hypersensitivity) to the drugs to be used during the study period (anesthetic ophthalmic solution, fluorescein, etc.) or similar drugs to the study medication.
- Those who wore contact lenses during the study period.
- Those who had participation in another clinical trial involving an investigational drug/device, or participation in such a trial within the last 30 days.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description latanoprost switch to tafluprost Latanoprost POAG and OH patients prescribed latanoprost(QID) at least 3 months (IOP\>20). At least one eye must have a score above 1 on the NEI scale. Switch to latanoprost (QID) for 3 months. latanoprost switch to tafluprost tafluprost POAG and OH patients prescribed latanoprost(QID) at least 3 months (IOP\>20). At least one eye must have a score above 1 on the NEI scale. Switch to latanoprost (QID) for 3 months.
- Primary Outcome Measures
Name Time Method Safety:Changes in the fluorescein staining score (NEI) at Visit 2 3 months fluorescein staining
Efficacy: Changes in the Intraocular Pressure (IOP) at each visit 3 months Tonometer
- Secondary Outcome Measures
Name Time Method Changes in the fluorescein staining score (NEI) at Visit 1 1 months fluorescein staining
Changes in ocular symptoms (irritation/burning/stinging, foreign body sensation, tearing, itching and dry eye sensation) at each visit 3 months Questionnaire
Changes in the Tear Break-Up Time (TBUT) at each visit 3 months slit-lamp
Changes in the hyperaemia at each visit 3 months slit-lamp
Treatment compliance 3 months Questionnaire
Concomitant medication 3 months Questionnaire
Patient satisfaction about test medication 3 months Questionnaire
Usability of eyedrop bottle 3 months Questionnaire
Adverse drug reactions 3 months Questionnaire
Trial Locations
- Locations (1)
Chi Mei Hospital Liouying Branch
🇨🇳Tainan, Taiwan